6 completed, 2 terminated, 1 active not recruiting, 1 withdrawn. 7 Phase 1, 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Terminated 2, Withdrawn 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow afuresertib: new trials by email Literature Review of afuresertib trials Research Report on afuresertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 Afuresertib, Nab paclitaxel, Docetaxel - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Completed | Laekna Limited | 22 | 2022-07-01 | 2025-11-17 |
| Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Afuresertib, Afuresertib/placebo - Breast Cancer | Phase 3 | Active not recruiting | Laekna Limited | 256 | 2022-02-18 | 2026-04-02 |
| PhI to Solid Tumors and PhII to Locally Advanced or mTNBC LAE005 + Afuresertib + Nab-Paclitaxel - Solid Tumor, TNBC - Triple-Negative Breast Cancer | Phase 1 | Completed | Laekna Limited | 21 | 2021-06-12 | 2024-10-10 |
| Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian Paclitaxel, Afuresertib - Platinum-resistant Ovarian Cancer | Phase 2 | Completed | Laekna Limited | 150 | 2020-07-07 | 2026-10-19 |
| Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC Phase I and Phase II: LAE001/prednisone + afuresertib - Metastatic Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Laekna Limited | 49 | 2019-09-13 | 2024-10-10 |
| Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone Afuresertib, Enzalutamide, Abiraterone - Cancer | Phase 1 | Withdrawn | GlaxoSmithKline | 2015-10-01 | 2016-10-06 | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) Afuresertib, Carfilzomib - Cancer | Phase 1 | Terminated | Novartis | 1 | 2014-11-01 | 2016-05-04 |
| Study of Afuresertib Combined With Paclitaxel in Gastric Cancer Afuresertib, Paclitaxel - Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 29 | 2014-10-01 | 2017-04-11 |
| Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients Afuresertib - Neoplasms, Haematologic | Phase 1 | Terminated | Novartis Pharmaceuticals | 9 | 2014-08-13 | 2021-08-11 |
| Continuation Study of the Oral AKT Inhibitor GSK2110183 GSK2110183 (afuresertib) - Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 11 | 2012-02-08 | 2019-07-09 |
Neoplasms (5) · Multiple Myeloma (2) · Breast Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Hematologic Neoplasms (1) · Recurrence (1) · Triple Negative Breast Neoplasms (1) · Uterine Cervical Neoplasms (1)
Laekna Limited (5) · Novartis Pharmaceuticals (3) · GlaxoSmithKline (1) · Novartis (1)
United States (5) · China (4) · South Korea (3) · Australia (1) · Canada (1) · Ireland (1) · Japan (1) · Taiwan (1)
Binghe NA Xu (1) · Herzog Thomas, Professor (1) · Lin Shen, Director (1) · Wenyue Ma (1) · Yong Yue, MD (1)
2014 (1)